50837-53-1

Basic information

• Product Name: 2,5-DIMETHYLBENZYL BROMIDE
• Synonyms: 2,5-DIMETHYLBENZYL BROMIDE;2,5-Dimethylbenzylbromid;2-(bromomethyl)-1,4-dimethylbenzene;Benzene,2-(bromomethyl)-1,4-dimethyl-;DHJPEGRMZQBUMM-UHFFFAOYSA-N
• CAS NO: 50837-53-1
• Molecular Formula: C₉H₁₁Br
• Molecular Weight: 199.09
• Mol File: 50837-53-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 233.837°C at 760 mmHg
• Flash Point: 100.583°C
• Appearance: /
• Density: 1.314g/cm³
• Vapor Pressure: 0.083mmHg at 25°C
• Refractive Index: 1.554
• CAS DataBase Reference: 2,5-DIMETHYLBENZYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-DIMETHYLBENZYL BROMIDE(50837-53-1)
• EPA Substance Registry System: 2,5-DIMETHYLBENZYL BROMIDE(50837-53-1)

Safety Data

• Statements: 34-36/37/38
• Safety Statements: 26-36/37/39
• RIDADR: 3265
• Hazardous Substances Data: 50837-53-1(Hazardous Substances Data)

Usage

General Description

2,5-DIMETHYLBENZYL BROMIDE, also known as alpha-bromo-2,5-dimethyltoluene, is a chemical compound with the formula C9H11Br. It is a colorless to pale yellow liquid that is soluble in organic solvents. 2,5-DIMETHYLBENZYL BROMIDE is primarily used as a reagent in organic synthesis, particularly in the production of pharmaceuticals and other fine chemicals. It is also used as an intermediate in the manufacturing of various compounds, such as flavors and fragrances. The compound is known for its strong and distinctive odor and should be handled with care, as it is toxic and harmful if swallowed, inhaled, or in contact with skin.

InChI:InChI=1/C9H11Br/c1-7-3-4-8(2)9(5-7)6-10/h3-5H,6H2,1-2H3

Upstream product

• 5779-94-2 2,5-dimethylbenzaldehyde 
• 50-00-0 formaldehyd 
• 106-42-3 para-xylene 
• 53957-33-8 2,5-dimethylbenzyl alcohol 

Downstream Products

• 13612-34-5 2-(2,5-dimethylphenyl)acetic acid 
• 6972-51-6 2-(2,5-dimethylphenyl)ethan-1-ol 
• 1090896-82-4 3-[3-(2,5-dimethyl-benzyl)-2-oxo-2,3-dihydro-benzoimidazol-1-yl]-hexanoic acid 
• 161865-25-4 2-(but-3-enyl)-1,4-dimethylbenzene 
• 1219938-06-3 2,2-dimethyl-3-(2,5-dimethylphenyl)propanal 
• 1370699-05-0 benzo[1,3]dioxole-5-carboxylic acid [3-(2,5-dimethylbenzyloxy)-4-(methanesulfonylamino)phenyl]amide 
• 1370699-06-1 benzo[1,3]dioxole-5-carboxylic acid {3-(2,5-dimethylbenzyloxy)-4-[(6-hydroxyhexyl)methanesulfonylamino]phenyl}amide 
• 1351646-50-8 4-[1-(2,5-dimethylbenzyl)-4-methoxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid 

Relevant articles and documents

TRIAZOLONE COMPOUNDS AS PERK INHIBITORS

The invention is directed to substituted triazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, X, Y, Y1, and Z are as defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Bromomethylation of aromatics mediated by low frequency ultrasound

We report herein bromomethylation of aromatics mediated by low frequency ultrasound to yield bromomethylated aromatic rings which are useful synthetic intermediates.